Allurion Technologies (ALUR) Projected to Post Quarterly Earnings on Wednesday

Allurion Technologies (NYSE:ALUR) is expected to post its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.63) per share and revenue of $2.95 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 12:30 PM ET.

Allurion Technologies Stock Performance

ALUR opened at $0.60 on Wednesday. The company has a market capitalization of $7.37 million, a PE ratio of -0.06 and a beta of -0.42. The stock’s fifty day moving average is $1.19 and its 200-day moving average is $1.56. Allurion Technologies has a one year low of $0.23 and a one year high of $4.18.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allurion Technologies in a report on Wednesday, January 21st. Loop Capital set a $3.00 price target on shares of Allurion Technologies in a report on Tuesday, February 24th. Finally, Chardan Capital set a $3.00 price objective on shares of Allurion Technologies and gave the company a “buy” rating in a research report on Tuesday, February 24th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Allurion Technologies presently has a consensus rating of “Hold” and a consensus target price of $7.33.

Institutional Trading of Allurion Technologies

Several hedge funds and other institutional investors have recently modified their holdings of ALUR. XTX Topco Ltd lifted its holdings in shares of Allurion Technologies by 43.2% in the second quarter. XTX Topco Ltd now owns 18,670 shares of the company’s stock valued at $45,000 after purchasing an additional 5,633 shares in the last quarter. State Street Corp raised its position in Allurion Technologies by 76.2% in the 4th quarter. State Street Corp now owns 26,135 shares of the company’s stock valued at $32,000 after buying an additional 11,300 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in Allurion Technologies in the 4th quarter valued at approximately $74,000. Heights Capital Management Inc. bought a new stake in Allurion Technologies in the 4th quarter valued at approximately $74,000. Finally, Armistice Capital LLC bought a new stake in Allurion Technologies in the 4th quarter valued at approximately $74,000. Institutional investors and hedge funds own 21.39% of the company’s stock.

About Allurion Technologies

Allurion Technologies is a medical technology company specializing in non-surgical weight-loss solutions. The company’s flagship product, the Allurion Gastric Balloon, is a swallowable, fluid-filled device designed to promote weight loss by creating a sense of fullness in the stomach. Unlike traditional intragastric balloons, the Allurion device does not require endoscopic insertion or removal, as it self-deflates and is naturally expelled after treatment, simplifying the patient experience and reducing clinical resource requirements.

In addition to its gastric balloon, Allurion has developed a comprehensive digital health platform that integrates wireless tracking devices, a mobile application, and remote coaching to support patients throughout their weight-loss journey.